An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies
Abstract
Authors
G. Giovannoni R. Gold R.J. Fox M. Kita M. Yang R. Zhang K.T. Dawson V. Viglietta S.I. Sheikh E. Havrdova